Please login to the form below
voxilaprevir
This page shows the latest voxilaprevir news and features for those working in and with pharma, biotech and healthcare.
Gilead wins European approval for triple hep C combination Vosevi
The treatment brings together sofosbuvir, velpatasvir and voxilaprevir. Gilead Sciences has chalked up a big win with its hepatitis C treatment Vosevi (sofosbuvir/velpatasvir/voxilaprevir) as it becomes the first and
Latest news
-
Gilead gets OK for three-in-one hep C therapy in US
The approval is believed to be the first for voxilaprevir anywhere in the world. ... Gilead has also filed for the sofosbuvir, velpatasvir and voxilaprevir therapy in the EU, winning an accelerated review from the EMA in January.
-
Samsung Bioepis wins CHMP nod for second Humira biosimilar
virus (infection) - AbbVie's Maviret (glecaprevir/pibrentasvir) and Gilead's Vosevi (sofosbuvir/velpatasvir/voxilaprevir).
-
Two new hepatitis C therapies fast-tracked in Europe
EU. Gilead's application is for a three drug combination of NS5B polymerase inhibitor sofosbuvir, NS5A inhibitor velpatasvir and pan-genotypic protease inhibitor voxilaprevir – given over 12 weeks – that could achieve
-
Gilead files hepatitis C salvage regimen in US
Seeks FDA approval for combination of Epclusa and voxilaprevir. The new generation of directly-acting antiviral (DAAs) have transformed the treatment of hepatitis C virus (HCV) infections - but not all patients ... inhibitor called voxilaprevir.
-
Gilead’s hepatitis C sales start to slide – the question is how quickly?
well as a triplet therapy based on sofosbuvir, velpatasvir and voxilaprevir that is in four late-stage trials.
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- New study identifies drugs that are safe to use in COVID-19 treatment
- Keytruda doubles five-year survival rate in NSCLC
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
